NO964548L - Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity - Google Patents

Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity

Info

Publication number
NO964548L
NO964548L NO964548A NO964548A NO964548L NO 964548 L NO964548 L NO 964548L NO 964548 A NO964548 A NO 964548A NO 964548 A NO964548 A NO 964548A NO 964548 L NO964548 L NO 964548L
Authority
NO
Norway
Prior art keywords
compounds
obesity
diabetes
levels
treatment
Prior art date
Application number
NO964548A
Other languages
Norwegian (no)
Other versions
NO964548D0 (en
Inventor
Michael H Fisher
Elisabeth M Naylor
Dong Ok
Ann E Weber
Thomas Shih
Hyun Ok
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/404,566 external-priority patent/US5541197A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO964548D0 publication Critical patent/NO964548D0/en
Publication of NO964548L publication Critical patent/NO964548L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Substituerte sulfonamider med formel (I) (R')n OH HR* '-N l l l /ri-\ A^CHCH,N-C.(X)m¿f \¿N-, -^-/ l \=|=/ l R3 Rs R»' (D med et egnet, substituert epoksid. Pre- parater og metoder for anvendelse av forbindelsene ved behandling av dia- betes og fedme, og for nedsettelse av triglyseridnivåer og kolesterolnivåer, eller for heving av høydensitetslipo- proteinnivåer eller for økning av tarm- motilitet, er også beskrevet. er selektive p3-adrenerge reseptoragon- ister med meget liten pt- og p2-adrenerg reseptoraktivitet, og som sådanne er forbindelsene i stand til å øke lipo- lyse og energiforbruk i celler. Forbin- delsene har således kraftig aktivitet ved behandling av diabetes type II og fedme. Forbindelsene kan også anvendes for å nedsette triglyseridnivåer og kolesterolnivåer, eller heve høydensi- tetslipoproteinnivåer eller redusere tarmmotilitet. I tillegg kan forbindel- sene anvendes for å redusere neurogen inflammasjon eller som antidepressive midler. Forbindelsene fremstilles ved kobling av et aminoalkylfenylsulfonamidSubstituted sulfonamides of formula (I) (R ') n OH HR *' -N lll / ri- \ A ^ CHCH, NC. (X) must \ ¿N-, - ^ - / l \ = | = / (D with a suitable substituted epoxide. Preparations and methods for the use of the compounds in the treatment of diabetes and obesity, and for the reduction of triglyceride levels and cholesterol levels, or for raising high-density lipoprotein levels or for gut motility is also described, selective p3 adrenergic receptor agonists with very little pt and p2 adrenergic receptor activity, and as such, the compounds are capable of increasing lipolysis and energy consumption in cells. Thus, they have potent activity in the treatment of type II diabetes and obesity.The compounds can also be used to decrease triglyceride levels and cholesterol levels, or raise high-density lipoprotein levels or reduce gut motility, as well as the compounds used to reduce neurogenic inflammation or as antidepressants. compound e is prepared by coupling an aminoalkylphenylsulfonamide

NO964548A 1994-04-26 1996-10-25 Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity NO964548L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23316694A 1994-04-26 1994-04-26
US40456595A 1995-03-21 1995-03-21
US08/404,566 US5541197A (en) 1994-04-26 1995-03-21 Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
PCT/US1995/004956 WO1995029159A1 (en) 1994-04-26 1995-04-21 SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Publications (2)

Publication Number Publication Date
NO964548D0 NO964548D0 (en) 1996-10-25
NO964548L true NO964548L (en) 1996-12-23

Family

ID=27398391

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964548A NO964548L (en) 1994-04-26 1996-10-25 Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity

Country Status (14)

Country Link
EP (1) EP0757674A1 (en)
JP (1) JP3149186B2 (en)
CN (1) CN1149869A (en)
AU (1) AU687558B2 (en)
CA (1) CA2187932A1 (en)
CZ (1) CZ315196A3 (en)
FI (1) FI964314A (en)
HU (1) HUT76442A (en)
IL (1) IL113410A (en)
NO (1) NO964548L (en)
NZ (1) NZ284718A (en)
PL (1) PL316969A1 (en)
SK (1) SK136196A3 (en)
WO (1) WO1995029159A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705515A (en) * 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
GB2305665A (en) * 1995-09-26 1997-04-16 Merck & Co Inc Selective ß3 agonists for the treatment of diabetes aand obesity
WO1997016189A1 (en) * 1995-11-01 1997-05-09 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
ES2208772T3 (en) 1996-01-10 2004-06-16 Asahi Kasei Kabushiki Kaisha NEW TRICYCLE COMPOUNDS AND PHARMACEUTICAL COMPOUNDS THAT CONTAIN THE SAME.
CA2257206A1 (en) * 1996-06-07 1997-12-11 Gui-Bai Liang Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity
AR007739A1 (en) * 1996-07-22 1999-11-10 Merck & Co Inc A PROCESS FOR THE PREPARATION OF N- (R) - (2-HYDROXY-2-PIRIDINE-3-IL-ETIL) -2- (4-NITRO-PHENYL) -ACETAMIDE
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
CA2270386C (en) * 1996-11-14 2004-08-03 Pfizer Inc. Process for substituted pyridines
ATE247641T1 (en) * 1996-11-14 2003-09-15 Pfizer PYRIDINE INTERMEDIATE PRODUCTS USABLE FOR PRODUCING BETA-ADRENERGIC RECEPTOR AGONISTS
TR199902442T2 (en) * 1997-01-28 2000-07-21 Merck & Co.,Inc. Thiazole benzenesulfonamides as β3 agonists in the treatment of sugar and obesity.
US6011048A (en) * 1997-01-28 2000-01-04 Merck & Co., Inc. Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
DK1028111T3 (en) * 1997-10-17 2004-09-20 Yamanouchi Pharma Co Ltd Amide derivatives or salts thereof
TW502032B (en) * 1997-12-19 2002-09-11 Bayer Ag Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6051586A (en) * 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6469031B1 (en) 1998-12-18 2002-10-22 Bayer Corporation Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6043253A (en) * 1998-03-03 2000-03-28 Merck & Co., Inc. Fused piperidine substituted arylsulfonamides as β3-agonists
MXPA03000308A (en) 2000-07-13 2003-06-06 Lilly Co Eli Beta3 adrenergic agonists.
US6451814B1 (en) * 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6498170B2 (en) * 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6537994B2 (en) * 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
AR035605A1 (en) 2000-12-11 2004-06-16 Bayer Corp DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS
EP1236723A1 (en) 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
AR035858A1 (en) 2001-04-23 2004-07-21 Bayer Corp CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS
EP1444224B1 (en) 2001-08-14 2006-05-03 Eli Lilly And Company 3-substituted oxindole beta-3 agonists
WO2003016307A1 (en) 2001-08-14 2003-02-27 Eli Lilly And Company β3 ADRENERGIC AGONISTS
ATE497948T1 (en) 2001-10-25 2011-02-15 Asahi Kasei Pharma Corp BICYCLIC COMPOUNDS
JP2005518357A (en) 2001-11-20 2005-06-23 イーライ・リリー・アンド・カンパニー Beta 3 adrenergic agonist
WO2003044016A1 (en) 2001-11-20 2003-05-30 Eli Lilly And Company 3-SUBSTITUTED OXINDOLE β3 AGONISTS
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004106290A1 (en) * 2003-05-14 2004-12-09 Kissei Pharmaceutical Co., Ltd. Amino alcohol derivatives, phamaceutical compositions containing the same, and use of both
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
DE102004021779A1 (en) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, process for their preparation and their use as medicines
JP4879988B2 (en) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2007145819A (en) * 2005-10-28 2007-06-14 Tanabe Seiyaku Co Ltd Pharmaceutical composition
DE102005052127A1 (en) 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel indole beta-agonists, process for their preparation and their use as pharmaceuticals
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JP5319518B2 (en) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 Indoledione derivative
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
AU2009301798B2 (en) 2008-10-09 2012-03-01 Asahi Kasei Pharma Corporation Indazole compound
CN102171191A (en) 2008-10-09 2011-08-31 旭化成制药株式会社 Indazole derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
PE20140859A1 (en) 2011-02-25 2014-07-25 Merck Sharp & Dohme NOVELTY DERIVATIVES OF CYCLIC AZABENZIMIDAZOLE USEFUL AS ANTIDIABETIC AGENTS
US9035059B2 (en) 2011-03-14 2015-05-19 Taisho Pharmaceutical Co., Ltd. Nitrogen-containing condensed heterocyclic compound
BR112015002080A2 (en) 2012-08-02 2017-07-04 Merck Sharp & Dohme compound, pharmaceutical composition, use of a compound, and method of treating or preventing a disorder, condition or disease
ES2394349B1 (en) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Use of selective beta-3 adrenergic receptor agonists for the treatment of pulmonary hypertension
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity

Also Published As

Publication number Publication date
IL113410A (en) 1999-11-30
NZ284718A (en) 1998-02-26
JP3149186B2 (en) 2001-03-26
IL113410A0 (en) 1995-07-31
HU9602951D0 (en) 1996-12-30
MX9605192A (en) 1997-09-30
CN1149869A (en) 1997-05-14
NO964548D0 (en) 1996-10-25
CA2187932A1 (en) 1995-11-02
HUT76442A (en) 1997-09-29
SK136196A3 (en) 1997-05-07
FI964314A0 (en) 1996-10-25
PL316969A1 (en) 1997-03-03
CZ315196A3 (en) 1997-08-13
WO1995029159A1 (en) 1995-11-02
AU687558B2 (en) 1998-02-26
AU2393795A (en) 1995-11-16
EP0757674A1 (en) 1997-02-12
FI964314A (en) 1996-10-25
JPH09512275A (en) 1997-12-09

Similar Documents

Publication Publication Date Title
NO964548L (en) Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity
DK0611003T3 (en) Substituted phenylsulfonamides as selective B3 agonists for the treatment of diabetes and obesity
HUP0002053A2 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
NO20006282L (en) New cyclosporins
DK0777712T3 (en) Polymer blends and their use as additives for petroleum intermediate distillates
DK0681571T3 (en) Spiro-substituted azacyclic compounds as tachykinin receptor antagonists
NO965235D0 (en) Oxaborols and salts thereof and their use as biocides
NO20070343L (en) N- (1- (1-benzyl-4-phenyl-1H-imidazol-2-yl) -2,2-dimethylpropyl) benzamide derivatives and related compounds such as quinine spindle protein (KSP) inhibitors for the treatment of cancer
NO991761L (en) New piperidine cotocarboxylic acid derivatives, their preparation and use
IT1232252B (en) DERIVATIVES OF N N PHENYL BENZAMIDE WITH ANTI-ULTER AND ANTIALLERIC ACTIVITY AND PROCEDURE FOR THEIR PREPARATION
NO944914L (en) Method of inhibiting autoimmune diseases
NO20003773L (en) Cyclobutene derivatives, their preparation and their therapeutic uses
AU6681786A (en) Aromatic thioethers
NO20001400L (en) Combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist
NO960179L (en) Use of indenoindole compounds
NO944933L (en) Procedure for inhibiting disease states of the breast
ATE173729T1 (en) BLOOD SUGAR-LOWERING DI-OXADIAZOLE DERIVATIVES
NO944924L (en) Procedures for inhibiting Turner's syndrome
WO1995001170A3 (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
Bose et al. Mechanics of guinea pig taenia coli smooth muscle during anoxia and rigor
CA2176971A1 (en) Preparation of Cisapride
NO962155L (en) New benzenesulfonylimine derivatives as inhibitors of IL action
EP0234573A3 (en) Reactive-dye-containing aqueous liquid composition
ATE261305T1 (en) USE OF A PYRIDAZINONE COMPOUND AS A CALCIUM SENSITIZER
Campbell et al. Comparative effects of bepridil and verapamil on isolated coronary and systemic vascular and cardiac muscle

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application